KCM
GILD icon

Kathmere Capital Management’s Gilead Sciences GILD Stock Holding History

Kathmere Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.38M Sell
26,787
-638
-2% -$84.1K 0.18% 103
2026
Q1 		$3.82M Sell
27,425
-822
-3% -$115K 0.24% 82
2025
Q4 		$3.47M Buy
28,247
+1,758
+7% +$214K 0.23% 79
2025
Q3 		$2.94M Buy
26,489
+1,510
+6% +$172K 0.21% 89
2025
Q2 		$2.77M Buy
24,979
+3,149
+14% +$335K 0.21% 88
2025
Q1 		$2.45M Buy
21,830
+4,303
+25% +$444K 0.21% 82
2024
Q4 		$1.62M Buy
17,527
+5,246
+43% +$472K 0.15% 97
2024
Q3 		$1.03M Buy
12,281
+2,266
+23% +$173K 0.1% 128
2024
Q2 		$687K Buy
10,015
+7,051
+238% +$471K 0.07% 146
2024
Q1 		$217K Buy
2,964
+460
+18% +$35.4K 0.02% 299
2023
Q4 		$203K Buy
+2,504
New +$195K 0.03% 278
2023
Q2 		– Sell
-2,776
Closed -$230K – 245
2023
Q1 		$230K Buy
+2,776
New +$230K 0.04% 182

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kathmere Capital Management's GILD Position: Q2 2026 in Review

Kathmere Capital Management reduced its Gilead Sciences (GILD) stake by 2.3% in Q2 2026, selling an estimated $84.1K and leaving 26,787 shares worth $3.38M. The position accounts for 0.18% of the portfolio, ranked #103.

Kathmere Capital Management first reported a position in GILD in Q1 2023 and has held it in 12 quarters since. The position peaked at $3.82M in Q1 2026. 2,285 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Kathmere Capital Management held 26,787 shares of Gilead Sciences worth $3.38M as of Q2 2026.
  • Kathmere Capital Management sold 638 Gilead Sciences shares in Q2 2026, an estimated $84.1K.
  • Gilead Sciences made up 0.18% of Kathmere Capital Management's portfolio in Q2 2026, its #103 holding.
  • Kathmere Capital Management first reported a position in Gilead Sciences in Q1 2023 and has held it in 12 quarters since.
  • Kathmere Capital Management's Gilead Sciences position peaked at $3.82M in Q1 2026.
  • 2,285 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Kathmere Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.